Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

SITC Introduces Guidelines for Anti–PD-1 Therapy in HNSCC

October 31st 2019

Based on strong findings for efficacy and safety, as well as FDA approvals, the Society for Immunotherapy of Cancer has issued the first guidelines for the use of immunotherapy agents in patients with recurrent or metastatic head and neck squamous cell carcinoma.

EU Panel Backs Pembrolizumab Regimens for Frontline HNSCC

October 18th 2019

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab as a monotherapy or in combination with platinum and 5-FU as frontline treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma and PD-L1 expression on their tumors.

Notable RET Inhibitor Trials Underway

October 18th 2019

The Next Steps in RET Inhibitor Research

October 18th 2019

Using RET Inhibitors in Clinical Practice

October 18th 2019

RET Inhibitor Trial Updates at ASCO and ESMO

October 18th 2019

How BLU-667 Has Changed the Treatment Landscape

October 18th 2019

ESMO 2019 LIBRETTO-001 Trial Updates

October 18th 2019

LOXO-292 in Patients With RET-Fusion Lung Cancer

October 18th 2019

LIBRETTO-001 Regimen Overview

October 18th 2019

RET Testing in Papillary and Medullary Thyroid Cancer

October 18th 2019

The Importance of NGS Testing

October 18th 2019

RET Treatment: Novel Compounds to Replace Current TKIs

October 18th 2019

Multikinase TKIs for NSCLC and Medullary Thyroid Cancer

October 18th 2019

RET Fusion, Point Mutation, and Signaling

October 18th 2019

Why RET Alteration is an Attractive Target for Therapy

October 18th 2019

Dr. Bourhis on the Rationale to Explore Debio 1143 in Head and Neck Cancer

October 17th 2019

Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the rationale to explore Debio 1143 in patients with head and neck cancer.

Dr. Gross on Neoadjuvant Cemiplimab in Head and Neck CSCC

October 12th 2019

Neil D. Gross, MD, FACS, discusses a phase II study of neoadjuvant cemiplimab in patients with stage III/IV cutaneous squamous cell carcinoma of the head and neck.

Dr. Saba Discusses Ongoing Research in Head and Neck Cancer

October 11th 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses ongoing research in head and neck cancer.

Dr. Bourhis on Results of the Phase II Trial With Debio 1143 in Head and Neck Cancer

October 10th 2019

Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the results of a phase II trial evaluating the addition of Debio 1143 to concurrent high-dose cisplatin and chemoradiation in high-risk patients with locally advanced squamous cell carcinoma of the head and neck.